Paul Crowe

Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation

Charlene Mason, Suzanne McFarlane, Patrick G. Johnston et al. · Molecular Cancer Therapeutics · 2008 · 92 citations · Full text

Medicine, Oncology, Pharmacology +16

RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin

Vittal Kurisetty, Patrick G. Johnston, Nicholas Johnston et al. · Oncogene · 2008 · 84 citations

Life Sciences, Oral Pathology, Signal Transduction +6

BRCA1 Suppresses Osteopontin-mediated Breast Cancer

Mohamed El‐Tanani, F C Campbell, Paul Crowe et al. · Journal of Biological Chemistry · 2006 · 32 citations · Full text

Medicine, Molecular Biology, Oncology +17

Synthesis of A83586C Analogs with Potent Anticancer and β-Catenin/ TCF4/Osteopontin Inhibitory Effects and Insights Into How A83586C Modulates E2Fs and pRb

Karl J. Hale, Soraya Manaviazar, Linos Lazarides et al. · Organic Letters · 2009 · 13 citations

Medicine, Oncology, Pharmacology +14

Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation

Lesley Powell, Paul Crowe, Chenchi Reddy Kankara et al. · Clinical Science · 2012 · 12 citations · Full text

Medicine, Endocrinology, Pharmacology +17